BRIEF—Nanobiotix appoints new chief medical officer

France’s Nanobiotix has appointed a new chief medical officer, Edwina Baskin-Bey, formerly CMO at Innocrin Pharmaceuticals.

At Innocrin, Dr Baskin-Bey led implementation of overall clinical and corporate strategy from Phase I to Phase III, and was responsible for medical, regulatory, pharmacovigilance, and other functions.

Chief executive Laurent Levy said: “As we advance development of NBTXR3 in multiple solid tumor indications and in combination with checkpoint inhibitors, Dr Baskin-Bey’s breadth and depth of experience align perfectly with our strategic leadership needs.”